Publications
2008
Analysis of cellular protein complexes by affinity purification and mass spectrometry.
Bürckstümmer T,
Bennett KL.
In Proteomics Methods Express 2008 (O’Connor CD and Hames BD, eds.), pp 119–134, Scion, Oxfordshire.
2007
Selective serotonin reuptake inhibitors – A new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol.
Schuster C,
Fernbach N,
Rix U,
Superti-Furga G,
Holy M,
Freissmuth M,
Sitte HH,
Sexl V.
2007, 74(9):1424–35.
2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets.
Rix U,
Hantschel O,
Dürnberger G,
Remsing Rix LL,
Planyavsky M,
Fernbach NV,
Kaupe I,
Bennett KL,
Valent P,
Colinge J,
Köcher T,
Superti-Furga G.
Blood. 2007, 110:4055–4063.
2007
The minimum information required for reporting a molecular interaction experiment (MIMIx).
Orchard S,
Salwinski L,
Kerrien S,
Montecchi- Palazzi L,
Oesterheld M,
Stumpflen V,
Ceol A,
Chatr-aryamontri A,
Armstrong J,
Woollard P,
Salama JJ,
Moore S,
Wojcik J,
Bader GD,
Vidal M,
Cusick ME,
Gerstein M,
Gavin AC,
Superti-Furga G,
et al.
Nat Biotechnol. 2007, 25(8):894–8.
2007
Mass spectrometry-based functional proteomics: from molecular machines to protein networks.
Kocher T,
Superti-Furga G.
Nat Methods. 2007, 4(10):807–15.
2007
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O,
Rix U,
Schmidt U,
Burckstummer T,
Kneidinger M,
Schutze G,
Colinge J,
Bennett KL,
Ellmeier W,
Valent P,
Superti-Furga G.
Proc Natl Acad Sci USA. 2007, 104:13283–13288.
